Tag: BioNTech

The market has a curious way of filtering noise. BioNTech's shares have climbed roughly 13 percent over the past month, ...

The market's patience with BioNTech has rarely been tested quite like this. The German biotech is juggling a halted colorectal ...

The arithmetic of BioNTech's current market position makes for uncomfortable reading. Regulatory approvals arrived in duplicate this week, yet the ...

BioNTech is entering a stretch where the story is being reshaped on two fronts at once: the numbers and the ...

Ugur Sahin and Özlem Türeci built BioNTech from a Mainz lab into a global vaccine powerhouse. By the end of ...

BioNTech enters a critical stretch with no single event to anchor investor sentiment. The German biotech’s stock closed at €80.20 ...

BioNTech is entering a period where scientific validation, financial discipline, and leadership transition all converge. The stock closed Tuesday at ...

BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as ...

The German biotech group BioNTech is sending two very different signals to the market at once. Its management is busy ...

The Mainz-based biotech firm finds itself in an unusual position: burning through cash on R&D while sitting on a €16.8 ...